Bullish Clene Insiders Loaded Up On US$9.58m Of Stock

1d ago, source:

Quite a few insiders have dramatically grown their holdings in Clene Inc. ( NASDAQ:CLNN ) over the past 12 months.

The Analyst Verdict: Clene In The Eyes Of 5 Experts

7d ago, source:

Providing deeper insights, analysts have established 12-month price targets, indicating an average target of $6.6, along with ...

Clene Inc. (NASDAQ: CLNN) Continues Development Of Lead Drug Candidate CNM Au8(R) For Neurodegenerative Diseases Including Parkinson's Disease

2d ago, source:

CNM-Au8 is an oral suspension with demonstrated activity in restoring neuronal health and function by increasing energy production and u ...

Clene Announces Peer-Reviewed Publication Characterizing the Protein Corona of the Investigational Neurodegenerative Disease Drug, CNM-Au8®

1mon ago, source: Business Insider

Clene Inc. (Nasdaq: CLNN) (along with its subsidiaries, “Clene”) and its wholly owned subsidiary Clene Nanomedicine Inc., a clinical-stage biopharmaceutical company focused on improving ...

Clene stock rallies 52% post-market on MS drug data

on MSN ago, source:

Clene (CLNN) stock rallied 52% post-market Tuesday after the company presented positive Phase 2 data for its drug CNM-Au8 in ...

Evidence for Clene’s CNM-Au8® as a Treatment for Repair and Remyelination in Multiple Sclerosis ...

8d ago, source: The Bakersfield Californian

Long term extension of the Phase 2 VISIONARY-MS clinical trial of CNM-Au8 demonstrated significant evidence of repair and remyelination across multiple paraclinical endpoints (change from original ...

Clene Inc. (CLNN)

9d ago, source: Yahoo Finance

Director and CEO of late clinical-stage biopharmaceutical company Clene Inc. (NASDAQ: CLNN), recently appeared on First in Human, a biotech-focused podcast featuring interviews with industry ...

Clene Inc Ordinary Shares

7d ago, source: Morningstar

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

Biomednewsbreaks - Clene Inc. (NASDAQ: CLNN) Looking To Advance Discussions For Accelerated Approval, New NDA For CNM-Au8(R) In 2024

13d ago, source:

Clene (NASDAQ: CLNN) , alongside its wholly owned subsidiary Clene Nanomedicine Inc., is a clinical-stage biopharmaceutical company focused on impro ...

Clene Reports Full Year 2023 Financial Results and Recent Operating Highlights

1mon ago, source: Stockhouse

Released long-term data from the open-label extension of the HEALEY ALS Platform Trial in which CNM-Au8 demonstrated statistically significant reductions of plasma neurofilament light chain (NfL) ...

Clene Reports Full Year 2023 Financial Results and Recent Operating Highlights

1mon ago, source: Yahoo Finance

SALT LAKE CITY, March 13, 2024 (GLOBE NEWSWIRE) -- Clene Inc. (Nasdaq: CLNN) (along with its subsidiaries, “Clene”) and its wholly owned subsidiary Clene Nanomedicine Inc., a clinical-stage ...